Whether it be taking a patient-ready product through the validation process for first in human clinical research use; translating a product from pre-human to human use; or developing production and analytical methods, our radiochemistry team work closely with stakeholders to achieve desired outcomes. Our knowledge of the Australian market and clinical sites can help connect development companies with clinics and clinicians with optimal patient populations. Our team is at the forefront of medical trends in drug development involving radiopharmaceuticals.
We work with stakeholders to take novel concepts and ideas from pre-clinical to clinical, supporting first in human trials, optimising labelling processes, analytical techniques and clinical production capabilities.
Members of our team have been at the forefront of Theranostics since it’s reinvigoration in the early 2000’s, right through to today’s cutting-edge alpha and beta peptide, small molecule and antibody radionuclide therapies.
We support leading radiopharmaceutical research by facilitating access to clinical trial participation. With our highly experienced clinical team we are able to assist in early phase clinical trials.
Our team has varied backgrounds including Radiopharmacy, Radiochemistry and Nuclear Medicine/PET. The diverse, highly experienced clinical and research expertise within our team is well situated to provide support. We work with hospitals, clinics and doctors from various health organisations, pharma companies and radionuclide suppliers.
We currently have transportation networks and partners that support the delivery of products across Melbourne, Sydney and throughout the rest of Australia. We also partner with local importers sourcing products from varied international suppliers.